DHEA, DHEAS and PCOS

Journal of Steroid Biochemistry and Molecular Biology

Volumn 145, Issue , 2015, Pages 213-225

  Goodarzi, Mark O ^a   Carmina, Enrico ^b   Azziz, Ricardo ^c  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b UNIVERSITY OF PALERMO   (Italy)

^c AUGUSTA UNIVERSITY   (United States)

Author keywords

Adrenal; Androgens; Dehydroepiandrosterone (DHEA); Dehydroepiandrosterone sulfate (DHEAS); Genetics; Polycystic ovary syndrome

Indexed keywords

ADRENAL PRECURSOR ANDROGEN; ANDROGEN; GLUCOSE; INSULIN; PRASTERONE; PRASTERONE SULFATE; UNCLASSIFIED DRUG; STEROID;

ANDROGEN BLOOD LEVEL; ANDROGEN SYNTHESIS; CARDIOVASCULAR RISK; GENETIC RISK; GLUCOSE BLOOD LEVEL; HERITABILITY; HUMAN; HYPERANDROGENISM; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; INSULIN BLOOD LEVEL; METABOLIC DISORDER; NONHUMAN; OBESITY; OVARY POLYCYSTIC DISEASE; PREVALENCE; REVIEW; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; STEROIDOGENESIS; ANIMAL; BLOOD; BODY MASS; CARDIOVASCULAR DISEASE; FEMALE; METABOLISM; PHENOTYPE; POLYCYSTIC OVARY SYNDROME;

ANDROGENS; ANIMALS; BODY MASS INDEX; CARDIOVASCULAR DISEASES; DEHYDROEPIANDROSTERONE; DEHYDROEPIANDROSTERONE SULFATE; FEMALE; HUMANS; HYPERANDROGENISM; PHENOTYPE; POLYCYSTIC OVARY SYNDROME; PREVALENCE; RISK FACTORS; STEROIDS;

EID: 84915756757     PISSN: 09600760     EISSN: 18791220     Source Type: Journal    
DOI: 10.1016/j.jsbmb.2014.06.003     Document Type: Review

References (165)

1. R. Azziz, E. Carmina, D. Dewailly, E. Diamanti-Kandarakis, H.F. Escobar-Morreale, W. Futterweit, O.E. Janssen, R.S. Legro, R.J. Norman, A.E. Taylor, and S.F. Witchel Positions statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an androgen excess society guideline J. Clin. Endocrinol. Metab. 91 2006 4237 4245
2. J.K. Zawadzki, and A. Dunaif Diagnostic criteria for polycystic ovary syndrome A. Dunaif, J. Givens, F. Haseltine, G.R. Merriam, Polycystic Ovary Syndrome 1992 Blackwell Scientific Publications Boston 377 384
3. The Rotterdam ESHRE/ASRM Sponsored PCOS Consensus Workshop Group Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome Fertil. Steril. 81 2004 19 25
4. The Rotterdam ESHRE/ASRM Sponsored PCOS Consensus Workshop Group Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS) Hum. Reprod. 19 2004 41 47
5. NIH Office of Disease Prevention: Evidence-based Methodology Workshop on Polycystic Ovary Syndrome (PCOS), Dec. 3-5, 2012-Final report (http://prevention.nih.gov/p2p/pcos/resources.aspx)
6. E.S. Knochenhauer, T.J. Key, M. Kahsar-Miller, W. Waggoner, L.R. Boots, and R. Azziz Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study J. Clin. Endocrinol. Metab. 83 1998 3078 3082
7. K.F. Michelmore, A.H. Balen, D.B. Dunger, and M.P. Vessey Polycystic ovaries and associated clinical and biochemical features in young women Clin. Endocrinol. (Oxf.) 51 1999 779 786
8. E. Diamanti-Kandarakis, C.R. Kouli, A.T. Bergiele, F.A. Filandra, T.C. Tsianateli, G.G. Spina, E.D. Zapanti, and M.I. Bartzis A survey of the polycystic ovary syndrome in the Greek island of Lesbos: hormonal and metabolic profile J. Clin. Endocrinol. Metab. 84 1999 4006 4011
9. M. Asunción, R.M. Calvo, J.L. San Millán, J. Sancho, S. Avila, and H.F. Escobar-Morreale A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain J. Clin. Endocrinol. Metab. 85 2000 2434 2438
10. R. Azziz, K.S. Woods, R. Reyna, T.J. Key, E.S. Knochenhauer, and B.O. Yildiz The prevalence and features of the polycystic ovary syndrome in an unselected population J. Clin. Endocrinol. Metab. 89 2004 2745 2749
11. C. Moran, G. Tena, S. Moran, P. Ruiz, R. Reyna, and X. Duque Prevalence of polycystic ovary syndrome and related disorders in Mexican women Gynecol. Obstet. Invest. 69 2010 274 280
12. W.A. March, V.M. Moore, K.J. Willson, D.I. Phillips, R.J. Norman, and M.J. Davies The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic criteria Human. Reprod. 25 2010 544 551
13. F. Mehrabian, B. Khani, R. Kelishadi, and E. Ghanbari The prevalence of polycystic ovary syndrome in Iranian women based on different diagnostic criteria Endokrynol. Pol. 62 2011 238 242
14. J.A. Boyle, J. Cunningham, K. O'Dea, T. Dunbar, and R.J. Norman Prevalence of polycystic ovary syndrome in a sample of indigenous women in Darwin, Australia Med. J. Aust. 196 2012 62 66
15. B.O. Yildiz, G. Bozdag, Z. Yapici, I. Esinler, and H. Yarali Prevalence, phenotype and cardiometabolic risk of polycystic ovary syndrome under different diagnostic criteria Hum. Reprod. 27 2012 3067 3073
16. H. Gill, P. Tiwari, and P. Dabadghao Prevalence of polycystic ovary syndrome in young women from North India: a community-based study Indian J. Endocrinol. Metab. 16 2012 S389 S392
17. R. Li, Q. Zhang, D. Yang, S. Li, S. Lu, X. Wu, Z. Wei, X. Song, X. Wang, S. Fu, J. Lin, Y. Zhu, Y. Jiang, H.L. Feng, and J. Qiao Prevalence of polycystic ovary syndrome in women in China: a large community-based study Hum. Reprod. 28 2013 2562 2569
18. S. Musmar, A. Afaneh, and H. Mo'alla Epidemiology of polycystic ovary syndrome a cross sectional study of university students at An-Najah national university-Palestine Reprod. Biol. Endocrinol. 11 2013 47 53
19. H. Rashidi, F. Ramezani Tehrani, M. Bahri Khomami, M. Tohidi, and F. Azizi To what extent does the use of the Rotterdam criteria affect the prevalence of polycystic ovary syndrome? A community-based study from the Southwest of Iran Eur. J. Obstet. Gynecol. Reprod. Biology 174 2014 100 105
20. M.P. Lauritsen, J.G. Bentzen, A. Pinborg, A. Loft, J.L. Forman, L.L. Thuesen, A. Cohen, D.M. Hougaard, and A. Nyboe Andersen The prevalence of polycystic ovary syndrome in a normal population according to the Rotterdam criteria versus revised criteria including anti-Mullerian hormone Hum. Reprod. 2014
21. F. Labrie, V. Luu-The, A. Bélanger, S.X. Lin, J. Simard, G. Pelletier, and C. Labrie Is dehydroepiandrosterone a hormone? J. Endocrinol. 187 2005 169 196
22. D. Lin, S.M. Black, Y. Nagahama, and W.L. Miller Steroid 17α-hydroxylase and 17,20 lyase activities of P450c17: contributions of serine106 and P450 reductase Endocrinology 132 1993 2498 2506
23. D. Lin, T. Sugawara, J.F. Strauss 3rd, B.J. Clark, D.M. Stocco, P. Saenger, A. Rogol, and W.L. Miller Role of steroidogenic acute regulatory protein in adrenal and gonadal steroidogenesis Science 267 1995 1828 1831
24. C. Longcope Adrenal and gonadal androgen secretion in normal females Clin. Endocrinol. Metab. 15 1986 213 228
25. X.G. Hui, J. Akahira, T. Suzuki, M. Nio, Y. Nakamura, H. Suzuki, W.E. Rainey, and H. Sasano Development of the human adrenal zona reticularis: morphometric and immunohistochemical studies from birth to adolescence J. Endocrinol. 203 2009 241 252
26. Y. Nakamura, P.J. Hornsby, P. Casson, R. Morimoto, F. Satoh, Y. Xing, M.R. Kennedy, H. Sasano, and W.E. Rainey Type 5 17β-hydroxysteroid dehydrogenase (AKR 1C3) contributes to testosterone production in the adrenal reticularis J. Clin. Endocrinol. Metab. 94 2009 2192 2198
27. J.C. Rijk, T.F. Bovee, A.A. Peijnenburg, M.J. Groot, I.M. Rietjens, and M.W. Nielen Bovine liver slices: a multifunctional in vitro model to study the prohormone dehydroepiandrosterone (DHEA) Toxicol. In Vitro 26 2012 1014 1021
28. F. Hammer, S. Subtil, P. Lux, C. Maser-Gluth, P.M. Stewart, B. Allolio, and W. Arlt No evidence for hepatic conversion of dehydroepiandrosterone (DHEA) sulfate to DHEA: in vivo and in vitro studies J. Clin. Endocrinol. Metab. 90 2005 3600 3605
29. F. Labrie, A. Bélanger, C. Labrie, B. Candas, L. Cusan, and J.L. Gomez Bioavailability and metabolism of oral and percutaneous dehydroepiandrosterone in postmenopausal women J. Steroid Biochem. Mol. Biol. 107 2007 57 69
30. Y. Xing, M.A. Edwards, C. Ahlem, M. Kennedy, A. Cohen, C.E. Gomez-Sanchez, and W.E. Rainey The effect of adrenocorticotrophic hormone on steroid metabolomic profiles in human adrenal cells J. Endocrinol. 209 2011 327 335
31. F. Labrie, A. Bélanger, L. Cusan, J.L. Gomez, and B. Candas Marked decline in serum concentrations of adrenal C19 sex steroid precursors and conjugated androgen metabolites during aging J. Clin. Endocrinol. Metab. 82 1997 2396 2402
32. A. Kumar, K.S. Woods, A.A. Bartolucci, and R. Azziz Prevalence of adrenal androgen excess in patients with the polycystic ovary syndrome (PCOS) Clin. Endocrinol. (Oxf.) 62 2005 644 649
33. S. Dharia, A. Slane, M. Jian, M. Conner, A.J. Conley, R.M. Brissie, and C.R. Parker Jr. Effects of aging on cytochrome b5 expression in the human adrenal gland J. Clin. Endocrinol. Metab. 90 2005 4357 4361
34. F.Z. Stanczyk Diagnosis of hyperandrogenism: biochemical criteria Best Pract. Res. Clin. Endocrinol. Metab. 20 2006 177 191
35. M. Pall, R. Azziz, J. Beires, and D. Pignatelli The phenotype of hirsute women: a comparison of polycystic ovary syndrome and 21-hydroxylase-deficient nonclassic adrenal hyperplasia Fertil. Steril. 94 2010 684 689
36. E. Carmina, F.Z. Stanczyk, L. Chang, R.A. Miles, and R.A. Lobo The ratio of androstenedione-11β-hydroxyandrostenedione is an important marker of adrenal androgen excess in women Fertil. Steril. 58 1992 1148 1152
37. D.I. Hoffman, K. Klove, and R.A. Lobo The prevalence and significance of elevated dehydroepiandrosterone sulfate levels in anovulatory women Fertil. Steril. 42 1984 76 81
38. E. Steinberger, K.D. Smith, and L.J. Rodriguez-Rigau Testosterone, dehydroepiandrosterone, and dehydroepiandrosterone sulfate in hyperandrogenic women J. Clin. Endocrinol. Metab. 59 1984 471 477
39. E. Carmina, F. Rosato, and A. Janni Increased DHEAS levels in PCO syndrome: evidence for the existence of two subgroups of patients J. Endocrinol. Invest. 9 1986 5 9
40. C. Moran, E. Knochenhauer, L.R. Boots, and R. Azziz Adrenal androgen excess in hyperandrogenism: relation to age and body mass Fertil. Steril. 71 1999 671 674
41. L.A. Sánchez, C. Morán, R. Reyna, T. Ochoa, L.R. Boots, and R. Azziz Adrenal progestogen and androgen production in 21-hydroxylase-deficient nonclassic adrenal hyperplasia is partially independent of adrenocorticotropic hormone stimulation Fertil. Steril. 77 2002 750 753
42. D. Miller, S.J. Emans, and I. Kohane Follow-up study of adolescent girls with a history of premature pubarche J. Adolesc. Health 18 1996 301 305
43. L. Ibanez, N. Potau, R. Virdis, M. Zampolli, C. Terzi, M. Gussinye, A. Carrascosa, and E. Vicens-Calvet Postpubertal outcome in girls diagnosed of premature pubarche during childhood: increased frequency of functional ovarian hyperandrogenism J. Clin. Endocrinol. Metab. 76 1993 1599 1603
44. L. Ibanez, N. Potau, M. Zampolli, M.E. Street, and A. Carrascosa Girls diagnosed with premature pubarche show an exaggerated ovarian androgen synthesis from the early stages of puberty: evidence from gonadotropin-releasing hormone agonist testing Fertil. Steril. 67 1997 849 855
45. T. Meas, D. Chevenne, E. Thibaud, J. Leger, S. Cabrol, P. Czernichow, and C. Levy-Marchal Endocrine consequences of premature pubarche in post-pubertal Caucasian girls Clin. Endocrinol. (Oxf.) 57 2002 101 106
46. L. Ibanez, J. Dimartino-Nardi, N. Potau, and P. Saenger Premature adrenarche - normal variant or forerunner of adult disease? Endocr. Rev. 21 2000 671 696
47. M. Maliqueo, T. Sir-Petermann, V. Perez, B. Echiburu, A.L. de Guevara, C. Galvez, N. Crisosto, and R. Azziz Adrenal function during childhood and puberty in daughters of women with polycystic ovary syndrome J. Clin. Endocrinol. Metab. 94 2009 3282 3288
48. R.A. Lobo, L.R. Granger, W.L. Paul, U. Goebelsmann, and D.R. Mishell Jr. Psychological stress and increases in urinary norepinephrine metabolites, platelet serotonin, and adrenal androgens in women with polycystic ovary syndrome Am. J. Obstet. Gynecol. 145 1983 496 503
49. J.H. Levin, E. Carmina, and R.A. Lobo Is the inappropriate gonadotropin secretion of patients with polycystic ovary syndrome similar to that of patients with adult-onset congenital adrenal hyperplasia? Fertil. Steril. 56 1991 635 640
50. E. Carmina, and R.A. Lobo Ovarian suppression reduces clinical and endocrine expression of late-onset congenital adrenal hyperplasia due to 21-hydroxylase deficiency Fertil. Steril. 62 1994 738 743
51. D. Dewailly, M.C. Vantyghem-Haudiquet, C. Sainsard, J. Buvat, J.P. Cappoen, K. Ardaens, A. Racadot, J. Lefebvre, and P. Fossati Clinical and biological phenotypes in late-onset 21-hydroxylase deficiency J. Clin. Endocrinol. Metab. 63 1986 418 423
52. C. Moran, R. Azziz, E. Carmina, D. Dewailly, F. Fruzzetti, L. Ibanez, E.S. Knochenhauer, J.A. Marcondes, B.B. Mendonca, D. Pignatelli, M. Pugeat, V. Rohmer, P.W. Speiser, and S.F. Witchel 21-hydroxylase-deficient nonclassic adrenal hyperplasia is a progressive disorder: a multicenter study Am. J. Obstet. Gynecol. 183 2000 1468 1474
53. H. Falhammar, M. Thoren, and K. Hagenfeldt A 31-year-old woman with infertility and polycystic ovaries diagnosed with non-classic congenital adrenal hyperplasia due to a novel CYP21 mutation J. Endocrinol. Invest. 31 2008 176 180
54. M.I. New Extensive clinical experience: nonclassical 21-hydroxylase deficiency J. Clin. Endocrinol. Metab. 91 2006 4205 4214
55. W.M. Hague, J. Adams, C. Rodda, C.G. Brook, R. de Bruyn, D.B. Grant, and H.S. Jacobs The prevalence of polycystic ovaries in patients with congenital adrenal hyperplasia and their close relatives Clin. Endocrinol. 33 1990 501 510
56. N.M. Stikkelbroeck, A.R. Hermus, D. Schouten, H.M. Suliman, G.J. Jager, D.D. Braat, and B.J. Otten Prevalence of ovarian adrenal rest tumours and polycystic ovaries in females with congenital adrenal hyperplasia: results of ultrasonography and MR imaging Eur. Radiol. 14 2004 1802 1806
57. G.E. Jones, J.E. Howard, and H. Langford The use of cortisone in follicular phase disturbances Fertil. Steril. 4 1953 49 62
58. R. Azziz, V.Y. Black, E.S. Knochenhauer, G.A. Hines, and L.R. Boots Ovulation after glucocorticoid suppression of adrenal androgens in the polycystic ovary syndrome is not predicted by the basal dehydroepiandrosterone sulfate level J. Clin. Endocrinol. Metab. 84 1999 946 950
59. R.J. Chang, F.P. Mandel, A.R. Wolfsen, and H.L. Judd Circulating levels of plasma adrenocorticotropin in polycystic ovary disease J. Clin. Endocrinol. Metab. 54 1982 1265 1267
60. P.M. Horrocks, F.R. Kandeel, D.R. London, W.R. Butt, S.S. Lynch, G. Holder, and R. Logan-Edwards ACTH function in women with the polycystic ovarian syndrome Clin. Endocrinol. 19 1983 143 150
61. A. Mongioi, M. Macchi, E. Vicari, M.C. Fornito, A.E. Calogero, C. Riccioli, G. Minacapilli, M.L. Moncada, and R. D'Agata Pituitary and adrenal response to ovine corticotropin-releasing hormone in women with polycystic ovarian syndrome J. Endocrinol. Invest. 11 1988 637 640
62. S.K. Cunningham, T. Loughlin, X. Bertagna, F. Girard, and T.J. McKenna Plasma pro-opiomelanocortin fragments and adrenal steroids following administration of metyrapone to normal and hirsute women J. Endocrinol. Invest. 11 1988 247 253
63. E. Carmina, J.H. Levin, G. Malizia, and R.A. Lobo Ovine corticotropin-releasing factor and dexamethasone responses in hyperandrogenic women Fertil. Steril. 54 1990 245 250
64. E. Carmina, and R.A. Lobo Pituitary adrenal responses to ovine corticotropin releasing hormone in polycystic ovary syndrome and other hyperandrogenic patients Gynecol. Endocrinol. 4 1990 225 231
65. P.M. Stewart, R. Penn, R. Holder, A. Parton, J.G. Ratcliffe, and D.R. London The hypothalamo-pituitary-adrenal axis across the normal menstrual cycle and in polycystic ovary syndrome Clin. Endocrinol. (Oxf.) 38 1993 387 391
66. A. Lanzone, M. Ciampelli, F. Petraglia, A. Caruso, A.M. Fulghesu, and S. Mancuso Corticotropin-releasing hormone induces and exaggerated response of adrenocorticotropic hormone and cortisol in polycystic ovary syndrome Fertil. Steril. 63 1995 1195 1199
67. R. Azziz, V. Black, G.A. Hines, L.M. Fox, and L.R. Boots Adrenal androgen excess in the polycystic ovary syndrome: sensitivity and responsivity of the hypothalamic-pituitary-adrenal axis J. Clin. Endocrinol. Metab. 83 1998 2317 2323
68. G. Gennarelli, J. Holte, M. Stridsberg, U. Lundqvist, M. Massobrio, T. Bäckström, and C. Berne Response of the pituitary-adrenal axis to hypoglycemic stress in women with the polycystic ovary syndrome J. Clin. Endocrinol. Metab. 84 1999 76 81
69. C. Invitti, M. De Martin, G. Delitala, J.D. Veldhuis, and F. Cavagnini Altered morning and nighttime pulsatile corticotropin and cortisol release in polycystic ovary syndrome Metabolism 47 1998 143 148
70. N. Cinar, A. Harmanci, D.Y. Aksoy, K. Aydin, and B.O. Yildiz Adrenocortical steroid response to ACTH in different phenotypes of non obese polycystic ovary syndrome J. Ovarian Res. 5 2012 42
71. D. Glintborg, A.P. Hermann, K. Brusgaard, J. Hangaard, C. Hagen, and M. Andersen Significantly higher adrenocorticotropin-stimulated cortisol and 17-hydroxyprogesterone levels in 337 consecutive, premenopausal, Caucasian, hirsute patients compared with healthy controls J. Clin. Endocrinol. Metab. 90 2005 1347 1353
72. R. Azziz Abnormalities of adrenocortical steroidogenesis in PCOS R. Azziz, J.E. Nestler, D. Dewailly, Androgen Excess Disorders in Women 1997 Lippincott-Raven Philadelphia 403 414
73. R.A. Lobo, and U. Goebelsmann Evidence for reduced 3 beta-ol-hydroxysteroid dehydrogenase activity in some hirsute women thought to have polycystic ovary syndrome J. Clin. Endocrinol. Metab. 53 1981 394 400
74. S.Y. Pang, A.J. Lerner, E. Stoner, L.S. Levine, S.E. Oberfield, I. Engel, and M.I. New Late-onset adrenal steroid 3 beta-hydroxysteroid dehydrogenase deficiency. I. A cause of hirsutism in pubertal and postpubertal women J. Clin. Endocrinol. Metab. 60 1985 428 439
75. S.F. Siegel, D.N. Finegold, R. Lanes, and P.A. Lee ACTH stimulation tests and plasma dehydroepiandrosterone sulfate levels in women with hirsutism N. Engl. J. Med. 323 1990 849 854
76. R. Azziz, E.L. Bradley Jr, H.D. Potter, and L.R. Boots 3 beta-hydroxysteroid dehydrogenase deficiency in hyperandrogenism Am. J. Obstet. Gynecol. 168 1993 889 895
77. C. Moran, H.D. Potter, R. Reyna, L.R. Boots, and R. Azziz Prevalence of 3beta-hydroxysteroid dehydrogenase-deficient nonclassic adrenal hyperplasia in hyperandrogenic women with adrenal androgen excess Am. J. Obstet. Gynecol. 181 1999 596 600
78. C. Lutfallah, W. Wang, J.I. Mason, Y.T. Chang, A. Haider, B. Rich, M. Castro-Magana, K.C. Copeland, R. David, and S. Pang Newly proposed hormonal criteria via genotypic proof for type II 3beta-hydroxysteroid dehydrogenase deficiency J. Clin. Endocrinol. Metab. 87 2002 2611 2622
79. G. Carbunaru, P. Prasad, B. Scoccia, P. Shea, N. Hopwood, F. Ziai, Y.T. Chang, S.E. Myers, J.I. Mason, and S. Pang The hormonal phenotype of Nonclassic 3 beta-hydroxysteroid dehydrogenase (HSD3B) deficiency in hyperandrogenic females is associated with insulin-resistant polycystic ovary syndrome and is not a variant of inherited HSD3B2 deficiency J. Clin. Endocrinol. Metab. 89 2004 783 794
80. C. Moran, R. Reyna, L.S. Boots, and R. Azziz Adrenocortical hyperresponsiveness to corticotropin in polycystic ovary syndrome patients with adrenal androgen excess Fertil. Steril. 81 2004 126 131
81. P.M. Stewart, C.H. Shackleton, G.H. Beastall, and C.R. Edwards 5 alpha-reductase activity in polycystic ovary syndrome Lancet 335 1990 431 433
82. D.A. Vassiliadi, T.M. Barber, B.A. Hughes, M.I. McCarthy, J.A. Wass, S. Franks, P. Nightingale, J.W. Tomlinson, W. Arlt, and P.M. Stewart Increased 5 alpha-reductase activity and adrenocortical drive in women with polycystic ovary syndrome J. Clin. Endocrinol. Metab. 94 2009 3558 3566
83. A. Rodin, H. Thakkar, N. Taylor, and R. Clayton Hyperandrogenism in polycystic ovary syndrome: evidence of dysregulation of 11β-hydroxysteroid dehydrogenase N. Engl. J. Med. 330 1994 460 465
84. R. Pasquali, D. Biscotti, G. Spinucci, V. Vicennati, A.D. Genazzani, L. Sgarbi, and F. Casimirri Pulsatile secretion of ACTH and cortisol in premenopausal women: effect of obesity and body fat distribution Clin. Endocrinol. 48 1998 603 612
85. P.M. Stewart, A. Boulton, S. Kumar, P.M. Clark, and C.H. Shackleton Cortisol metabolism in human obesity: impaired cortisone-cortisol conversion in subjects with central adiposity J. Clin. Endocrinol. Metab. 84 1999 1022 1027
86. R. Andrew, D.I. Phillips, and B.R. Walker Obesity and gender influence cortisol secretion and metabolism in man J. Clin. Endocrinol. Metab. 83 1998 1806 1809
87. A. Gambineri, G. Forlani, A. Munarini, F. Tomassoni, G.E. Cognigni, W. Ciampaglia, U. Pagotto, B.R. Walker, and R. Pasquali Increased clearance of cortisol by 5beta-reductase in a subgroup of women with adrenal hyperandrogenism in polycystic ovary syndrome J. Endocrinol. Invest. 32 2009 210 218
88. T. Tsilchorozidou, J.W. Honour, and G.S. Conway Altered cortisol metabolism in polycystic ovary syndrome: insulin enhances 5alpha-reduction but not the elevated adrenal steroid production rates J. Clin. Endocrinol. Metab. 88 2003 5907 5913
89. F. Roelfsema, P. Kok, A.M. Pereira, and H. Pijl Cortisol production rate is similarly elevated in obese women with or without the polycystic ovary syndrome J. Clin. Endocrinol. Metab. 95 2010 3318 3324
90. E. Carmina, and R.A. Lobo Prevalence and metabolic characteristics of adrenal androgen excess in hyperandrogenic women with different phenotypes J. Endocrinol. Invest. 30 2007 111 116
91. R. Azziz, F.L. Gay, S.R. Potter, E. Bradley Jr., and L.R. Boots The effects of prolonged hypertestosteronemia on adrenocortical biosynthesis in oophorectomized women J. Clin. Endocrinol. Metab. 72 1991 1025 1030
92. G.A. Hines, E.R. Smith, and R. Azziz Influence of insulin and testosterone on adrenocortical steroidogenesis in vitro: preliminary studies Fertil. Steril. 76 2001 730 735
93. A. Kumar, D. Magoffin, I. Munir, and R. Azziz Effect of insulin and testosterone on androgen production and transcription of SULT2A1 in the NCI-H295R adrenocortical cell line Fertil. Steril. 92 2009 793 797
94. R. Azziz, R.S. Rittmaster, L.M. Fox, E.L. Bradley Jr., H.D. Potter, and L.R. Boots Role of the ovary in the adrenal androgen excess of hyperandrogenic women Fertil. Steril. 69 1998 851 859
95. F. Gonzalez, D.A. Hatala, and L. Speroff Adrenal and ovarian steroid hormone responses to gonadotropin-releasing hormone agonist treatment in polycystic ovary syndrome Am. J. Obstet. Gynecol. 165 1991 535 545
96. E. Carmina, F. Gonzalez, L. Chang, and R.A. Lobo Reassessment of adrenal androgen secretion in women with polycystic ovary syndrome Obstet. Gynecol. 6 1995 26
97. M.I. Cedars, K.A. Steingold, D. de Ziegler, P.S. Lapolt, R.J. Chang, and H.L. Judd Long-term administration of gonadotropin-releasing hormone agonist and dexamethasone: assessment of the adrenal role in ovarian dysfunction Fertil. Steril. 57 1992 495 500
98. R. Azziz, W.Y. Chang, F.Z. Stanczyk, and K. Woods Effect of bilateral oophorectomy on adrenocortical function in women with polycystic ovary syndrome Fertil. Steril. 99 2013 599 604
99. G.A. Burghen, J.R. Givens, and A.E. Kitabchi Correlation of hyperandrogenism with hyperinsulinism in polycystic ovarian disease J. Clin. Endocrinol. Metab. 50 1980 113 116
100. J.E. Nestler, L.P. Powers, D.W. Matt, K.A. Steingold, S.R. Plymate, R.S. Rittmaster, J.N. Clore, and W.G. Blackard A. direct effect of hyperinsulinemia on serum sex hormone-binding globulin levels in obese women with the polycystic ovary syndrome J. Clin. Endocrinol. Metab. 72 1991 83 89
101. K. Brennan, A. Huang, and R. Azziz Dehydroepiandrosterone sulfate and insulin resistance in patients with polycystic ovary syndrome Fertil. Steril. 91 2009 1848 1852
102. R.P. Kauffman, V.M. Baker, P. DiMarino, and V.D. Castracane Hyperinsulinemia and circulating dehydroepiandrosterone sulfate in white and Mexican American women with polycystic ovary syndrome Fertil. Steril. 85 2006 1010 1016
103. R.P. Buyalos, E.L. Bradley Jr., H.L. Judd, H.A. Zacur, and R. Azziz No acute effect of physiological insulin increase on dehydroepiandrosterone sulfate in women with obesity and/or polycystic ovarian disease Fertil. Steril. 56 1991 1179 1182
104. R.P. Buyalos, M.E. Geffner, R. Azziz, and H.L. Judd Impact of overnight dexamethasone suppression on the adrenal androgen response to an oral glucose tolerance test in women with and without polycystic ovary syndrome Hum. Reprod. 12 1997 1138 1141
105. R. Azziz, E.L. Bradley Jr., H.D. Potter, C.R. Parker Jr., and L.R. Boots Chronic hyperinsulinemia and the adrenal androgen response to acute corticotropin-(1-24) stimulation in hyperandrogenic women Am. J. Obstet. Gynecol. 172 1995 1251 1256
106. A.K. Ludwig, L.G. Goharian, T. Dietze, S. Tauchert, S. Rudolf, K. Diedrich, U. Schweiger, and K.M. Oltmanns Impact of glycemic variations on the regulation of androgen metabolism in obese women with polycystic ovary syndrome Fertil. Steril. 92 2009 271 276
107. M.P. Diamond, D. Grainger, A.J. Laudano, K. Starick-Zych, and R.A. DeFronzo Effect of acute physiological elevations of insulin on circulating androgen levels in nonobese women J. Clin. Endocrinol. Metab. 72 1991 883 887
108. L. Farah-Eways, R. Reyna, E.S. Knochenhauer, A.A. Bartolucci, and R. Azziz Glucose action and adrenocortical biosynthesis in women with polycystic ovary syndrome Fertil. Steril. 81 2004 120 125
109. T. Falcone, D.T. Finegood, I.G. Fantus, and D. Morris Androgen response to endogenous insulin secretion during the frequently sampled intravenous glucose tolerance test in normal and hyperandrogenic women J. Clin. Endocrinol. Metab. 71 1990 1653 1657
110. R. Azziz, D.A. Ehrmann, R.S. Legro, A.G. Fereshetian, M. O'Keefe, and M.N. Ghazzi Troglitazone decreases adrenal androgen levels in women with polycystic ovary syndrome Fertil. Steril. 79 2003 932 937
111. K. Rautio, J.S. Tapanainen, A. Ruokonen, and L.C. Morin-Papunen Endocrine and metabolic effects of rosiglitazone in overweight women with PCOS: a randomized placebo-controlled study Hum. Reprod. 21 2006 1400 1407
112. V. Sepilian, and M. Nagamani Effects of rosiglitazone in obese women with polycystic ovary syndrome and severe insulin resistance J. Clin. Endocrinol. Metab. 90 2005 60 65
113. M. Guido, D. Romualdi, R. Suriano, M. Giuliani, B. Costantini, R. Apa, and A. Lanzone Effect of pioglitazone treatment on the adrenal androgen response to corticotrophin in obese patients with polycystic ovary syndrome Hum. Reprod. 19 2004 534 539
114. D. Romualdi, M. Giuliani, G. Draisci, B. Costantini, F. Cristello, A. Lanzone, and M. Guido Pioglitazone reduces the adrenal androgen response to corticotropin-releasing factor without changes in ACTH release in hyperinsulinemic women with polycystic ovary syndrome Fertil. Steril. 88 2007 131 138
115. E. Aigner, N. Bachofner, K. Klein, C. De Geyter, F. Hohla, W. Patsch, and C. Datz Retinol-binding protein 4 in polycystic ovary syndrome - association with steroid hormones and response to pioglitazone treatment J. Clin. Endocrinol. Metab. 94 2009 1229 1235
116. D. Glintborg, A.P. Hermann, C. Hagen, L.T. Jensen, J. Frystyk, P. Bennett, A. Flyvbjerg, and M. Andersen A randomized placebo-controlled study on the effects of pioglitazone on cortisol metabolism in polycystic ovary syndrome Fertil. Steril. 91 2009 842 850
117. X.J. Li, Y.X. Yu, C.Q. Liu, W. Zhang, H.J. Zhang, B. Yan, L.Y. Wang, S.Y. Yang, and S.H. Zhang Metformin vs thiazolidinediones for treatment of clinical, hormonal and metabolic characteristics of polycystic ovary syndrome: a meta-analysis Clin. Endocrinol. (Oxf.) 74 2011 332 339
118. A. Majuri, M. Santaniemi, K. Rautio, A. Kunnari, J. Vartiainen, A. Ruokonen, Y.A. Kesaniemi, J.S. Tapanainen, O. Ukkola, and L. Morin-Papunen Rosiglitazone treatment increases plasma levels of adiponectin and decreases levels of resistin in overweight women with PCOS: a randomized placebo-controlled study Eur. J. Endocrinol. 156 2007 263 269
119. V.P. Sepilian, J.R. Crochet, and M. Nagamani Serum soluble leptin receptor levels and free leptin index in women with polycystic ovary syndrome: relationship to insulin resistance and androgens Fertil. Steril. 85 2006 1441 1447
120. W. Arlt, R.J. Auchus, and W.L. Miller Thiazolidinediones but not metformin directly inhibit the steroidogenic enzymes P450c17 and 3beta -hydroxysteroid dehydrogenase J. Biol. Chem. 276 2001 16767 16771
121. S.A. Arslanian, V. Lewy, K. Danadian, and R. Saad Metformin therapy in obese adolescents with polycystic ovary syndrome and impaired glucose tolerance: amelioration of exaggerated adrenal response to adrenocorticotropin with reduction of insulinemia/insulin resistance J. Clin. Endocrinol. Metab. 87 2002 1555 1559
122. A. la Marca, G. Morgante, T. Paglia, L. Ciotta, A. Cianci, and V. De Leo Effects of metformin on adrenal steroidogenesis in women with polycystic ovary syndrome Fertil. Steril. 72 1999 985 989
123. M. Ehrhart-Bornstein, J.P. Hinson, S.R. Bornstein, W.A. Scherbaum, and G.P. Vinson Intraadrenal interactions in the regulation of adrenocortical steroidogenesis Endocr. Rev. 19 1998 101 143
124. J.P. Forney, L. Milewich, G.T. Chen, J.L. Garlock, B.E. Schwarz, C.D. Edman, and P.C. MacDonald Aromatization of androstenedione to estrone by human adipose tissue in vitro. Correlation with adipose tissue mass, age, and endometrial neoplasia J. Clin. Endocrinol. Metab. 53 1981 192 199
125. G.E. Ackerman, M.E. Smith, C.R. Mendelson, P.C. MacDonald, and E.R. Simpson Aromatization of androstenedione by human adipose tissue stromal cells in monolayer culture J. Clin. Endocrinol. Metab. 53 1981 412 417
126. S.E. Bulun, and E.R. Simpson Competitive reverse transcription-polymerase chain reaction analysis indicates that levels of aromatase cytochrome p450 transcripts in adipose tissue of buttocks, thighs, and abdomen of women increase with advancing age J. Clin. Endocrinol. Metab. 78 1994 428 432
127. R. Azziz, H.A. Zacur, C.R. Parker Jr., E.L. Bradley Jr., and L.R. Boots Effect of obesity on the response to acute adrenocorticotropin stimulation in eumenorrheic women Fertil. Steril. 56 1991 427 433
128. V. Vicennati, F. Calzoni, A. Gambineri, L. Gagliardi, A.M. Morselli Labate, F. Casimirri, and R. Pasquali Secretion of major adrenal androgens following ACTH administration in obese women with different body fat distribution Hormone Metab. Res. 30 1998 133 136
129. R.S. Rittmaster, N. Deshwal, and L. Lehman The role of adrenal hyperandrogenism, insulin resistance, and obesity in the pathogenesis of polycystic ovarian syndrome J. Clin. Endocrinol. Metab. 76 1993 1295 1300
130. S. Brody, K. Carlstrom, A. Lagrelius, N.O. Lunell, and G. Mollerstrom Adrenal steroids in post-menopausal women relation to obesity and to bone mineral content Maturitas 9 1987 25 32
131. S. Komindr, B.R. Kurtz, M.D. Stevens, J.G. Karas, J.B. Bittle, and J.R. Givens Relative sensitivity and responsivity of serum cortisol and two adrenal androgens to alpha-adrenocorticotropin-(1-24) in normal and obese, nonhirsute, eumenorrheic women J. Clin. Endocrinol. Metab. 63 1986 860 864
132. V. Vicennati, and R. Pasquali Abnormalities of the hypothalamic-pituitary-adrenal axis in nondepressed women with abdominal obesity and relations with insulin resistance: evidence for a central and a peripheral alteration J. Clin. Endocrinol. Metab. 85 2000 4093 4098
133. E. Carmina, S. Bucchieri, A. Esposito, A. Del Puente, P. Mansueto, G. Di Fede, and G.B. Rini Abdominal fat quantity and distribution in women with polycystic ovary syndrome and extent of its relation to insulin resistance J. Clin. Endocrinol. Metab. 92 2007 2500 2505
134. J.I. Rotter, F.L. Wong, E.T. Lifrak, and L.N. Parker A genetic component to the variation of dehydroepiandrosterone sulfate Metabolism 34 1985 731 736
135. E.C. Prom-Wormley, T.P. York, K.C. Jacobson, L.J. Eaves, S.P. Mendoza, D. Hellhammer, N. Maninger, S. Levine, S. Lupien, M.J. Lyons, R. Hauger, H. Xian, C.E. Franz, and W.S. Kremen Genetic and environmental effects on diurnal dehydroepiandrosterone sulfate concentrations in middle-aged men Psychoneuroendocrinology 36 2011 1441 1452
136. T. Rice, D.L. Sprecher, I.B. Borecki, L.E. Mitchell, P.M. Laskarzewski, and D.C. Rao The Cincinnati Myocardial Infarction and Hormone Family study: family resemblance for dehydroepiandrosterone sulfate in control and myocardial infarction families Metabolism 42 1993 1284 1290
137. P. An, T. Rice, J. Gagnon, Y. Hong, A.S. Leon, J.S. Skinner, J.H. Wilmore, C. Bouchard, and D.C. Rao Race differences in the pattern of familial aggregation for dehydroepiandrosterone sulfate and its responsiveness to training in the HERITAGE Family Heart Study Metabolism 50 2001 916 920
138. C.E. Jaquish, J. Blangero, S.M. Haffner, M.P. Stern, and J.W. Maccluer Quantitative genetics of dehydroepiandrosterone sulfate and its relation to possible cardiovascular disease risk factors in Mexican Americans Hum. Hered. 46 1996 301 309
139. B.D. Mitchell, C.M. Kammerer, J. Blangero, M.C. Mahaney, D.L. Rainwater, B. Dyke, J.E. Hixson, R.D. Henkel, R.M. Sharp, A.G. Comuzzie, J.L. VandeBerg, M.P. Stern, and J.W. MacCluer Genetic and environmental contributions to cardiovascular risk factors in Mexican Americans. The San Antonio Family Heart Study Circulation 94 1996 2159 2170
140. C.E. Jaquish, M.C. Mahaney, J. Blangero, S.M. Haffner, M.P. Stern, and J.W. MacCluer Genetic correlations between lipoprotein phenotypes and indicators of sex hormone levels in Mexican Americans Atherosclerosis 122 1996 117 125
141. H. Li, and C. Ji Change of dehydroepiandrosterone in serum of 6-18 year-old twin girls in Qingdao city Wei Sheng Yan Jiu 36 2007 41 42
142. A.W. Meikle, J.D. Stringham, M.G. Woodward, and D.T. Bishop Heritability of variation of plasma cortisol levels Metabolism 37 1988 514 517
143. A.W. Meikle, R.A. Stephenson, C.M. Lewis, G.A. Wiebke, and R.G. Middleton Age genetic, and nongenetic factors influencing variation in serum sex steroids and zonal volumes of the prostate and benign prostatic hyperplasia in twins Prostate 33 1997 105 111
144. J.E. Nestler, J.B. Whitfield, T.Y. Williams, G. Zhu, J. Condon, K.M. Kirk, A.C. Heath, G.W. Montgomery, and N.G. Martin Genetics of serum dehydroepiandrosterone sulfate and its relationship to insulin in a population-based cohort of twin subjects J. Clin. Endocrinol. Metab. 87 2002 682 686
145. Y. Akamine, K. Kato, and H. Ibayashi Studies on changes in the concentration of serum adrenal androgens in pubertal twins Acta Endocrinol. (Copenh.) 93 1980 356 364
146. B.O. Yildiz, M.O. Goodarzi, X. Guo, J.I. Rotter, and R. Azziz Heritability of dehydroepiandrosterone sulfate in women with polycystic ovary syndrome and their sisters Fertil. Steril. 86 2006 1688 1693
147. S. Franks, L.J. Webber, M. Goh, A. Valentine, D.M. White, G.S. Conway, S. Wiltshire, and M.I. McCarthy Ovarian morphology is a marker of heritable biochemical traits in sisters with polycystic ovaries J. Clin. Endocrinol. Metab. 93 2008 3396 3402
148. M.O. Goodarzi, X. Guo, B.O. Yildiz, F.Z. Stanczyk, and R. Azziz Correlation of adrenocorticotropin steroid levels between women with polycystic ovary syndrome and their sisters Am. J. Obstet. Gynecol. 196 398 2007 e391 e395
149. R.S. Legro, A.R. Kunselman, L. Demers, S.C. Wang, R. Bentley-Lewis, and A. Dunaif Elevated dehydroepiandrosterone sulfate levels as the reproductive phenotype in the brothers of women with polycystic ovary syndrome J. Clin. Endocrinol. Metab. 87 2002 2134 2138
150. M.O. Goodarzi, H.J. Antoine, and R. Azziz Genes for enzymes regulating dehydroepiandrosterone sulfonation are associated with levels of dehydroepiandrosterone sulfate in polycystic ovary syndrome J. Clin. Endocrinol. Metab. 92 2007 2659 2664
151. Y.V. Louwers, F.H. de Jong, N.A. van Herwaarden, L. Stolk, B.C. Fauser, A.G. Uitterlinden, and J.S. Laven Variants in SULT2A1 affect the DHEA sulphate to DHEA ratio in patients with polycystic ovary syndrome but not the hyperandrogenic phenotype J. Clin. Endocrinol. Metab. 98 2013 3848 3855
152. M. Komori, K. Nishio, M. Kitada, K. Shiramatsu, K. Muroya, M. Soma, K. Nagashima, and T. Kamataki Fetus-specific expression of a form of cytochrome P-450 in human livers Biochemistry 29 1990 4430 4433
153. P. Kuehl, J. Zhang, Y. Lin, J. Lamba, M. Assem, J. Schuetz, P.B. Watkins, A. Daly, S.A. Wrighton, S.D. Hall, P. Maurel, M. Relling, C. Brimer, K. Yasuda, R. Venkataramanan, S. Strom, K. Thummel, M.S. Boguski, and E. Schuetz Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression Nat. Genet. 27 2001 383 391
154. P. Smit, R.H. van Schaik, M. van der Werf, A.W. van den Beld, J.W. Koper, J. Lindemans, H.A. Pols, A.O. Brinkmann, F.H. de Jong, and S.W. Lamberts A common polymorphism in the CYP3A7 gene is associated with a nearly 50% reduction in serum dehydroepiandrosterone sulfate levels J. Clin. Endocrinol. Metab. 90 2005 5313 5316
155. M.O. Goodarzi, N. Xu, and R. Azziz Association of CYP3A7∗1C and serum dehydroepiandrosterone sulfate levels in women with polycystic ovary syndrome J. Clin. Endocrinol. Metab. 93 2008 2909 2912
156. H.F. Escobar-Morreale, J.L. San Millan, R.R. Smith, J. Sancho, and S.F. Witchel The presence of the 21-hydroxylase deficiency carrier status in hirsute women: phenotype-genotype correlations Fertil. Steril. 72 1999 629 638
157. S.F. Witchel, M. Kahsar-Miller, C.E. Aston, C. White, and R. Azziz Prevalence of CYP21 mutations and IRS1 variant among women with polycystic ovary syndrome and adrenal androgen excess Fertil. Steril. 83 2005 371 375
158. L. Vandenput, and C. Ohlsson Genome-wide association studies on serum sex steroid levels Mol. Cell. Endocrinol. 382 2014 758 766
159. G. Zhai, A. Teumer, L. Stolk, J.R. Perry, L. Vandenput, A.D. Coviello, A. Koster, J.T. Bell, S. Bhasin, J. Eriksson, A. Eriksson, F. Ernst, L. Ferrucci, T.M. Frayling, D. Glass, E. Grundberg, R. Haring, A.K. Hedman, A. Hofman, D.P. Kiel, H.K. Kroemer, Y. Liu, K.L. Lunetta, M. Maggio, M. Lorentzon, M. Mangino, D. Melzer, I. Miljkovic, A. Nica, B.W. Penninx, R.S. Vasan, F. Rivadeneira, K.S. Small, N. Soranzo, A.G. Uitterlinden, H. Volzke, S.G. Wilson, L. Xi, W.V. Zhuang, T.B. Harris, J.M. Murabito, C. Ohlsson, A. Murray, F.H. de Jong, T.D. Spector, and H. Wallaschofski Eight common genetic variants associated with serum DHEAS levels suggest a key role in ageing mechanisms PLoS Genet. 7 2011 e1002025
160. Z.J. Chen, H. Zhao, L. He, Y. Shi, Y. Qin, Z. Li, L. You, J. Zhao, J. Liu, X. Liang, X. Zhao, Y. Sun, B. Zhang, H. Jiang, D. Zhao, Y. Bian, X. Gao, L. Geng, Y. Li, D. Zhu, X. Sun, J.E. Xu, C. Hao, C.E. Ren, Y. Zhang, S. Chen, W. Zhang, A. Yang, J. Yan, J. Ma, and Y. Zhao Genome-wide association study identifies susceptibility loci for polycystic ovary syndrome on chromosome 2p16. 3, 2p21 and 9q33. 3 Nat. Genet. 43 2011 55 59
161. Y. Shi, H. Zhao, Y. Shi, Y. Cao, D. Yang, Z. Li, B. Zhang, X. Liang, T. Li, J. Chen, J. Shen, J. Zhao, L. You, X. Gao, D. Zhu, X. Zhao, Y. Yan, Y. Qin, W. Li, J. Yan, Q. Wang, J. Zhao, L. Geng, J. Ma, Y. Zhao, G. He, A. Zhang, S. Zou, A. Yang, J. Liu, W. Li, B. Li, C. Wan, Y. Qin, J. Shi, J. Yang, H. Jiang, J.E. Xu, X. Qi, Y. Sun, Y. Zhang, C. Hao, X. Ju, D. Zhao, C.E. Ren, X. Li, W. Zhang, Y. Zhang, J. Zhang, D. Wu, C. Zhang, L. He, and Z.J. Chen Genome-wide association study identifies eight new risk loci for polycystic ovary syndrome Nat. Genet. 44 2012 1020 1025
162. L. Cui, H. Zhao, B. Zhang, Z. Qu, J. Liu, X. Liang, X. Zhao, J. Zhao, Y. Sun, P. Wang, T. Li, Y. Shi, and Z.J. Chen Genotype-phenotype correlations of PCOS susceptibility SNPs identified by GWAS in a large cohort of Han Chinese women Hum. Reprod. 28 2013 538 544
163. K.T. Khaw Dehydroepiandrosterone, dehydroepiandrosterone sulphate and cardiovascular disease J. Endocrinol. 150 1996 S149 S153
164. C. Ohlsson, F. Labrie, E. Barrett-Connor, M.K. Karlsson, O. Ljunggren, L. Vandenput, D. Mellström, and A. Tivesten Low serum levels of dehydroepiandrosterone sulfate predict all-cause and cardiovascular mortality in elderly Swedish men J. Clin. Endocrinol. Metab. 95 2010 4406 4414
165. C. Shufelt, P. Bretsky, C.M. Almeida, B.D. Johnson, L.J. Shaw, R. Azziz, G.D. Braunstein, C.J. Pepine, V. Bittner, D.A. Vido, F.Z. Stanczyk, and C.N. Bairey Merz DHEA-S levels and cardiovascular disease mortality in postmenopausal women: results from the National Institutes of Health? National Heart, Lung, and Blood Institute (NHLBI)-sponsored Women's Ischemia Syndrome Evaluation (WISE) J. Clin. Endocrinol. Metab. 95 2010 4985 4992